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Abstract
Hyperglycemia has been associated with vascular endothelial dysfunction in part by a
reduction in nitric oxide (NO) production and increased oxidative stress (e.g., increased
superoxide (SO) and hydrogen peroxide (H2O2). Endothelial-derived NO can be significantly
reduced by increased SO/H2O2 in part by the activation of NADPH oxidase during
hyperglycemia. Of the 7 NADPH oxidase isoforms, NADPH oxidase isoform 1 (NOX1) is
mainly expressed in the vasculature and may play a major role in hyperglycemia induced
oxidative stress and vascular endothelial dysfunction. This hypothesis was tested by
measuring blood NO and H2O2 levels in real time via NO and H2O2 microsensors inserted
into femoral veins of rats. Hyperglycemia (e.g., 200 mg/dl) was maintained by an i.v.
infusion of 30% glucose solution for 3 hours with or without a selective NOX1 inhibitor,
ML171. Hyperglycemia for 3 hours resulted in significantly higher blood H2O2 levels
(3.06±0.4 μM, n=9) compared to the saline infused control (P<0.01, n=9). By contrast,
ML171 (1 and 5 μM) reduced hyperglycemia-induced H2O2 levels by 1.86±0.61 μM
(P<0.05, n=8) and 4.85±1.02 μM (P<0.01, n=5) respectively relative to the hyperglycemic
control after 3 hours. Hyperglycemia also significantly reduced blood NO levels
(101.41±10.91 nM, n=8) compared to the saline control (P<0.01, n=8) after 3 hours. By
contrast, ML171 (1 and 5 μM) significantly attenuated the hyperglycemia induced decrease
in blood NO levels and increased blood NO levels by 68.48±12.67 nM (P<0.01, n=5) and
85.95±12.67 nM (P<0.01, n=5) respectively relative to the hyperglycemic control, at the end
of experiment. Our results indicate that NOX1 activation may contribute to hyperglycemiainduced oxidative stress and NO reduction. Furthermore, inhibition of NOX1 may mitigate
the deleterious effects of hyperglycemia.
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Introduction

Chronic hyperglycemia in diabetic patients is causally related to micro- and
macro-vascular complications. Diabetic patients can have decreased wound healing,
decreased immune function, increased oxidative stress, vascular endothelial
dysfunction, and increased inflammatory factors1. Uncontrolled hyperglycemia can
lead to arterial remodeling and atherogenesis, which may result in blocked arteries
provoking cardiovascular events. Similarly, acute or stress hyperglycemia in nondiabetic patients can lead to increased myocardial infarction size, negative postsurgical consequences, such as infection, increased morbidity, and mortality2.
However, the vascular damage due to uncontrolled hyperglycemia has not been yet
contained in medical practice. Therefore, understanding the underlying cause of
these vascular and inflammatory events during hyperglycemia is critical for better
clinical management.

Diabetes Mellitus
Diabetes mellitus is a medical condition that has become an epidemic and a
public health concern in recent years. The International Diabetes Federation
estimates the current prevalence rate of 9.3% will be doubled by 20353. The
American Diabetes Association confirms that 1.4 million Americans are diagnosed
every year and 86 million Americans have prediabetes3. The CDC reports Diabetes
is the 7th leading cause of death, recording over 75,000 deaths in 20144. The expert
committee on the diagnosis and classifications for diabetes mellitus criteria of
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diagnosis is having hyperglycemia (high blood glucose) of or above 126 mg/dL
while fasting for 8 hours due to insulin deficiency (type I) or resistance (type II) on
more than one occurrence5. Resistance to insulin is usually due to obesity or
association with a metabolic syndrome. The normal range for blood glucose levels
are between 70 and 100 mg/dL. Key complications of Diabetes are micro- and
macro-vascular complications, such as hypertension, cardiovascular disease,
blindness, kidney disease, and lower-limb amputation1. In 2003-2006,
cardiovascular disease death rates were 1.7 times higher among patients with
diabetes than without4. In 2010, the CDC also had confirmed that hospitalization
rates for heart attacks and strokes were 1.8 and 1.5 times more likely in patients
with diabetes respectively4. The CDC also reported that from 2005-2008, 4.2 million
(28.5%) adult diabetes patients had diabetic retinopathy and 4.4% had advanced
retinopathy, which could lead to severe vision loss4. Moreover, diabetes is
responsible for 44% of all kidney failure cases in 20114. Finally, 60% of nontraumatic lower limb amputations occurred in patients diagnosed with diabetes4.

Acute Hyperglycemia
Acute hyperglycemia, otherwise known as stress hyperglycemia is defined as
a condition in which blood glucose levels are above 126 mg/dL temporarily, without
a known history of diabetes5. It is typically due to surgery, critical illness, sepsis,
and/or trauma. It has been reported that stress hyperglycemia occurs 5-30%
critical illness cases6. Although acute hyperglycemia does not have all the
deleterious impacts on a patient as diabetes, it still has been linked to numerous
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complications such as a decrease in wound healing and immune function, an
increase in myocardial infarctions (MI), post-surgical complications, extended
hospital stays, as well as increased mortality rates. Yang et al (2009) determined
that acute hyperglycemia increased infarct size (% region at risk) in mice from 34%
to 49% (a 45% increase in infarct size)13. In 2009, Cruz-Gonzalez et al. found a
correlation between non-diabetic patients admitted with hyperglycemia and
increase in infarct size. They discovered that hyperglycemia was an independent
predictor of infarct size and that hyperglycemia was associated with a larger infarct
size23. A randomized study by Richards et al (2014) demonstrate that surgical site
infections (SSI) in orthopedic injuries were more common in patients with
hyperglycemia (21.2%) than without (3.3%)16. On a cellular level hyperglycemia
has been linked to vascular endothelial dysfunction and subsequent inflammatory
responses 10.

Vascular Endothelial Cells and Vascular Endothelial Function
Endothelial cells are a single layer of mesenchymal cells that line body
cavities and vascular walls. Endothelial cells specific to the lining of arteries, veins,
and capillaries of the skin, heart, lungs, and brain are continuous and
nonfenestrated, meaning there is no breaks in the endothelial lining and they lack
pores for rapid exchange of molecules10. They contain caveolae as well as transient
receptor potential channels that assist in regulating fluid and macromolecule
passage as well as vascular regeneration, increased permeability and endotheliumderived NO mediated vasorelaxation10. These cells produce factors such as
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vasodilators (NO, prostaglandins,etc), vasoconstrictors (angiotensin II and
endothelin-1), pro and anticoagulants (plasminogen activators and inhibitors,
thrombomodulin, von Wilebrand factor,etc), and fibrinolytics and anti-fibrinolytics,
growth factors (VEGF), to maintain normal vascular homeostasis or in response to
vascular damages, respectively10. Their luminal surfaces are capable of regulating
trafficking of blood cells through their binding proteins and other molecules.
Endothelial cells are also involved in innate and adaptive immunity as well as
hemostasis by releasing inflammatory and anti-inflammatory factors (NO), adhesion
factors (E-selectin, PECAM-1, VCAM-1, ICAM-1), as well as oxidizing and
antioxidizing factors10. Vascular endothelial cells play a key role in maintaining
vascular homeostasis, vessel regulation, blood clotting and inflammation, as
summarized by Favero et al. in figure 1. In particular, endothelial nitric oxide
synthase (eNOS) is a key component in vascular endothelial cells.

Figure 1: Functions of Endothelial Cells in Physiological Conditions.
Received from Favero, G. et al. Endothelium and Its Alterations in Cardiovascular
Diseases: Life Style Intervention. BioMed Research International. 1-28. (2014)
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Endothelial nitric oxide synthase (eNOS)
Endothelial nitric oxide synthase (eNOS), is diffusely distributed in the
cytoplasm of endothelial cells10. Endothelial cells express higher levels of eNOS
after stress. The enzyme releases NO which not only prevents inflammation,
coagulant signals, and facilitates blood flow, but it is a key factor for maintaining
vascular tone and reactivity. NO is also responsible for inhibiting platelet and white
blood cell activation and prevents actions of contracting factors such as angiotensin
II and endothelin-1 (ET-1)10. The eNOS enzyme has two domains with two separate
functions, C-terminal reductase domain and an N-terminal oxygenase domain14.
The C-terminal reductase domain produces electrons by way of FAD/NADPH and
the FMN binding sequences it contains. The N-terminal oxygenase domain binds
BH4 and L-arginine and converts L-arginine to L-citrulline, and in the process,
produces NO. Both BH4 and L-arginine are essential for the generation of NO, as
demonstrated by early studies showing that depletion of these factors results in SO
formation instead of NO, which is described as eNOS uncoupling14.

eNOS Uncoupling and SO Induced by Oxidative Stress
In pathological conditions, oxidative stress can induce eNOS uncoupling,
which shifts its product from NO to SO. This shift from NO to SO also occurs in the
N-terminal oxygenase domain, specifically at it’s heme center. Recent studies also
have also shown evidence that the C-terminal reductase domain produces SO in its
FAD/NADPH and FMN binding sites14. It has been understood for some time now
that in the presence of SO, it can quickly quench nitric oxide (NO) to form
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peroxynitrite, another more toxic free radical. Peroxynitrite is responsible for
uncoupling eNOS by oxidizing the complex as well as its cofactor BH4, demonstrated
in figure 218.

Figure 2: Functions of eNOS, coupled and uncoupled.
Retrieved from Schmidt, T. et al. Mechanisms for the role of tetrahydrobiopterin in
endothelial function and vascular disease. Clin Sci (Lond). 113(2):47-63
Youn, et al has also recently demonstrated recently, that Bone Morphogenic
Protein 4 (BMP4), which is known for its activity during inflammation, endothelial
dysfunction, and atherogenesis, has been linked to eNOS uncoupling17. This was
demonstrated by increased SO production as well as a decrease in BH4. They also
determined in this same study that NOX1 mediates BMP4-induced eNOS uncoupling,
as shown by a diminished BMP4-induced eNOS uncoupling with NOX1 siRNAtransfected cells17. The product shift of uncoupled eNOS from NO to SO not only
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diminishes NO bioavailability, but also increases SO products, resulting in greater
oxidative stress.

Vascular Endothelial Dysfunction Under Hyperglycemic Conditions
Many studies have suggested that chronic and acute hyperglycemia can cause
vascular endothelial dysfunction. A meta-analysis conducted in 2015 documented
that the effects of hyperglycemia are responsible for decreased macro- vascular
function. Studies have demonstrated that macro-vascular function such as
endothelium-dependent vasodilation through NO was also decreased due to acute
hyperglycemia and suggests that acute hyperglycemia could be responsible for the
vascular smooth muscle cell proliferation that is responsible for vascular
remodeling, resulting in cardiovascular disease24.
The deleterious effects of hyperglycemia have been presumed to be initiated
by vascular endothelial dysfunction. In type 1 diabetes, endothelial dysfunction is
chiefly due to metabolic changes predominantly at the retinal and kidney level,
however, in type 2 diabetes, endothelial dysfunction begins before onset13.
Oxidative stress is believed to be a source of vascular endothelial dysfunction and
increased inflammatory factors. Oxidative stress is due to overproduced reactive
oxygen species (ROS) overwhelming anti-oxidant mechanisms in the body. ROS that
mainly consist of overproduced superoxide (SO) and hydrogen peroxide (H2O2). SO
can be readily converted to H2O2 by superoxide dismutase (SOD). H2O2 is much
more stable than SO and remains for longer periods in the blood. There are multiple
sources of ROS, as previously mentioned, uncoupled eNOS, as well as mitochondria
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under dysfunction, xanthine oxidase, and NADPH oxidase26. All of these upregulate
their production of SO under pathological conditions and in upregulation of NADPH
oxidase26.
As previously mentioned, overproduced SO can quickly quench nitric oxide
(NO) to form peroxynitrite resulting in reduced endothelial-derived NO
bioavailability. Vascular endothelial dysfunction is not only identified by increased
levels of ROS, but also by decreased levels of nitric oxide (NO). Oxidative stress has
been linked continuously to the progression of all types of diabetes as well as other
pathological conditions. Many sources have concluded that hyperglycemia is the
cause of increased ROS, which then leads to other complications20,21.

NADPH Oxidases
NADPH oxidases are the only enzymes in the body that naturally produce
SO/ H2O2. NADPH oxidases and also may be a principle source of SO/ H2O2 under
hyperglycemic conditions that result in eNOS uncoupling. There are a total of 7
isoforms in mammals, NOX -1, -2, -3, -4, -5, and dual oxidase -1/-2. NOX1 through 3
share similar structures consisting of five subunits. Each of these contains two
transmembrane units, the NOX unit which is the catalytic unit, and the p22phox
unit. They also contain three cytosolic subunits, RAC1 which is a small GTPase
responsible for regulation, p47phox/NOXO1 which is responsible for organization,
and NoxA1/p67phox which is responsible for activation. Angiotensin II (Ang II) is
responsible for the upregulation of vascular NADPH oxidases in physiological
conditions through activation of protein kinase C (PKC). Once PKC is activated, it is
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translocated to the membrane where it can phosphorylate the p47phox subunit of
NADPH oxidase. This phosphorylation causes assembly of the rest of the subunits
while also triggers activation of a proto-oncogene, c-Src, to stimulate epidermal
growth factor receptor (EGRF), creating a cascade of activations to activate the Rac1
subunit and in turn activate NADPH oxidase22.

Figure 3: NADPH Oxidase 1 Structure and Composition.
Retrieved from Drummond, G, et al. Combating Oxidative stress in vascular disease:
NADPH oxidases as therapeutic targets. 453-471. (2011)
NADPH oxidases are responsible for electron transfer into the electron
transport chain with oxygen as the final acceptor. This electron transfer results in
the NADPH oxidase releasing superoxide. Some isoforms, such as Nox4, Duox1 and
Duox 2 release hydrogen peroxide instead. As previously stated, superoxide(SO) is
not as stable as hydrogen peroxide(H2O2) and is quickly converted. These enzymes
are located in the constitutive cell’s arterial walls and are responsible for generation
of ROS which leads to oxidative stress. In physiological conditions, NADPH oxidases
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(NOX) assist the body with innate immunity, redox-dependent signaling, and
production of hormones.
In pathological conditions, NADPH oxidases are responsible for the over
production of ROS and oxidative stress in the body. In pathological conditions, an
up regulation of NADPH oxidase activation and activity thus leads to an increased
and detrimental amount of ROS which causes irreversible damage to the
vasculature. NADPH oxidases are activated under hyperglycemic conditions
through PKC. During hyperglycemia, the increased levels of glucose are responsible
for providing increased levels of diacylglycerol (DAG) through glycolysis. DAG is
responsible for activating PKC, and has been accepted as the DAG-PKC pathway.
This pathway has been known to regulate endothelial permeability as well as
vascular function5. Upregulation of PKC in turn upregulates activation of NADPH
oxidases.
PKC enzymes, specifically PKC Beta II become activated by hyperglycemia
and translocate to the membrane. This translocation as previously stated, puts
them in proximity with the NADPH oxidases, causing phosphorylation of the NOX
p47phox subunit. Phosphorylation of this subunit stimulates the rest of the NOX
subunits to assemble, thus activating the NADPH oxidase.
It has also been recently discovered that NADPH oxidases may also have a
role in activation of mitochondrial dysfunction through AngII22. Dikalov found that
inhibition of NADPH oxidases as well as PKC, prevented of mitochondrial
dysfunction22. Their studies show that mitochondrial function is associated with
NADPH oxidase specific SO. When there is an upregulation of SO and H2O2 by
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NADPH oxidase, there is an opening of the mitoKATP channels, which leads to the
dysfunction22. This was demonstrated by using the NADPH oxidase inhibitors,
apocynin and chelerythrine, which prevented mitochondrial dysfunction.
Mitochondrial dysfunction leads to decreased membrane potential, respiratory
control ratio, and the content of low molecular weight thiols. The results of
mitochondrial dysfunction include increased SO and H2O2 production on the
mitochondrial complex I. When the mitochondria had an increase in SO, there was
an increase in cytoplasmic SO as well, suggesting that the mitochondria in turn
upregulated NADPH oxidase activity22. This further exacerbates the oxidative stress
caused by NADPH oxidases, and creates a “cross-talk” of sorts between
mitochondria and NADPH oxidases that results in a feed forward mechanism for
oxidative stress22. The study suggests that this cross talk activity could be mediated
by c-Src.. Of the NADPH oxidases, only 1,2 and 4 are expressed in the vasculature,
and only 1 and 2 in endothelial cells.
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Figure 4. The possible vicious cycle involved in hyperglycemia-induced
vascular endothelial dysfunction and oxidative stress.

NADPH Oxidase 1 (NOX1) and NADPH Oxidase 2 (NOX2)
Most NADPH oxidase isoforms are expressed in each cell type of the vascular
wall. Of these isoforms, NOX1 and NOX2 are mainly expressed in the vascular
endothelial cells and vascular smooth muscle cells (VSMCs). Previous animal studies
have determined NOX1 to be the main isoform associated with cardiovascular
disease pathology3. Previous studies also showed that NOX1 mRNA levels were
elevated in the kidney during hyperglycemic conditions as well as deletion of NOX1
attenuating hyperglycemic induced glomerular hypertrophy, mesangial matrix
expansion, oxidative stress and cortical senescence, all of which are associated with
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renal disease8. NOX1 activity has also been linked as the major component of ROS
and inflammatory cytokine induced beta cell dysfunction11.
NOX2, on the other hand, did not show any attenuation of such factors
causing diabetic kidney when tested with NOX2 Knock out mice9. Previously, our
lab has found NOX2 inhibitor, gp91ds-tat, only partially reduced blood H2O2 levels
under hyperglycemic conditions. However, the role of NOX1 in hyperglycemia
induced oxidative stress and vascular endothelial dysfunction is still unclear.

NOX1 Inhibitor: ML171
High-throughput screening has identified a few phenothiazines that exhibit
NOX1 inhibition. It was discovered that 2-acetylphenothiazine, otherwise known as
ML171, is currently the inhibitor most specific for NOX1, while having only marginal
activity with other NADPH oxidases12.

ML171 was shown to have a 30-fold

selectivity over other NOX isotypes. This inhibitor works specifically and directly on
the Nox1 subunit, previously mentioned as the catalytic unit of the enzyme. It has
been previously discovered that ML171 blocked ROS-dependent formation of
extracellular matrix-degrading invadopodia in colon cancers and was reversed
when over expression f NOX1 was introduced. ML171 was the selective NOX1
inhibitor as it is the best available at that time.
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Hypothesis
It was hypothesized that acute hyperglycemia (200 mg/dL) would increase
blood H2O2 levels and decrease blood NO levels compared to saline control. By
inhibiting NADPH Oxidase 1 phosphorylation/assembly/activation through
ML171(2-acetylphenothiazine, MW=241.31 g/mol, Tocris Bioscience), acute
hyperglycemia-induced vascular dysfunction would be attenuated. This will be
confirmed by decreased blood H2O2 levels and increased blood NO levels compared
to acute hyperglycemia control.
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Methods
NO and H2O2 Calibrations
Microsensors (100m, World Precision Instruments (WPI), Sarasota, FL) for
NO and H2O2 were calibrated prior to the experiments using known concentrations
of NO and H2O2 as per manufacturer’s suggestion. The electrochemical
microsensors membrane detects the NO and H2O2 and is analyzed in real-time using
the Apollo 4000 Free Radical Anaylzer that allows measurement of multiple species
at once and selective poise voltage for ranges needed. Standard curves were used to
convert electrochemical changes to concentrations. Standard curves for NO were
achieved by soaking the microsensor in 10 mL copper sulfate. The baseline was
recorded after at least 10 minutes of soaking, followed by added known amounts (0200 nM) of standard SNAP solution (100M- 00022 g S-Nitroso-N-Acetyl-D,LPenicillamine (SNAP) and 0.002 g ethylenediaminetetraaceitic acid (EDTA) were
dissolved in 100 mL distilled water) were added and the differences were recorded.
To obtain a standard curve for H2O2, the microsensor was soaked in 10 mL PBS
buffer until stabilized. Following the baseline measurement, known amounts (0-2
M) of standard (1mM) H2O2 was added to develop a calibration formula. The
formulas determined from both standard curves were used to convert
measurements obtained in real-time to concentrations of blood NO (nM) and blood
H2O2 (M).
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Animal Preparations
All the procedures used in the animal experiments were approved by PCOM
IACUC. Male Sprague-Dawley rats (Charles River: Charles River Kinston, NC),
ranging from 275-325g, were used in this study. The rats were anesthetized with
pentobarbital sodium 60mg/kg of 50mg/mL injections (i. p.). Maintenance doses
were titrated to effect at 30mg/kg (i.p.). Surgical preparations to prepare animal for
infusions and monitoring throughout the 180 minutes of the experiment are
illustrated in figures 4 and 5.

Figure 5. Isolation and catheterization of Jugular vein and Carotid artery.
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Figure 6. Catheterization of both Femoral veins with inserted microsensors.

The carotid artery was first catheterized in order to monitor status during
the experiment (see figure 4-blue arrow). Proper operative conditions were
monitored by recording mean arterial blood pressure (MABP) every 20 minutes,
throughout the experimental period.

Normal MABP levels ranged from 90-

130mmHg during the entire experiment. The jugular vein was catheterized to
infuse saline, 30% D-glucose, or 30% D-glucose with ML171 (see figure 4-black
arrow). Dose dependency was evaluated using 1M and 5M doses of ML171.
Following, 1 mL Heparin was then administered to preclude blood clotting during
intravenous infusion, as well as MABP monitoring via the carotid artery, and blood
adherence to the membranes of the free radical sensors inserted into the femoral
vein catheters. Hyperglycemic conditions were induced with a loading dose of 30%
D-glucose at 0.33mL/min for 3 minutes. Blood glucose levels were maintained
around 200mg/dL for 3 hours by measuring blood glucose levels every 20 minutes
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using a blood glucose meter and adjusting infusion rate accordingly (0.0180.025mL/min). To determine NO and H2O2 levels in real time throughout the
experiment, NO and H2O2 microsensors were inserted into catheters in both femoral
veins and measured using the free radical analyzer (see figure 5). Levels of NO and
H2O2 were be measured as pA every 20 minutes until the end of the experiment and
converted into concentration (nM for NO and μM for H2O2, respectively) using the
calibration curves.

Experimental Groups
There were 4 experimental groups:
1. Saline Controls (n=8 for NO and n=9 for H2O2) The animals had the same
surgical conditions as experimental groups and were monitored for NO and
H2O2 in a similar manner for 3-hour experimental period following the 1hour baseline readings. This group was used to demonstrate stability of the
physiological parameters under surgery, to demonstrate real-time NO and
H2O2 levels, and served as a control for the to hyperglycemic group.
2. Hyperglycemic groups (n=8 for NO and n=9 for H2O2) These animals were
initially infused with 30% glucose to induce hyperglycemia then infused
continuously with 30% glucose to maintain hyperglycemic conditions of
≥200 mg/dL throughout the experiment. The groups were used to
demonstrate real-time NO and H2O2 under hyperglycemic conditions.
3. Hyperglycemic groups + 1 μM ML171 (n=5 for NO and n=8 for H2O2) These
animals were initially infused with 30% glucose to induce hyperglycemia
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then infused continuously with 30% glucose to maintain hyperglycemic
conditions of ≥200 mg/dL throughout the experiment. These groups were
used to demonstrate real-time NO and H2O2 under hyperglycemic conditions
with the addition of the NOX1 inhibitor.
4. Hyperglycemic groups + 5 1 μM ML171 (n=5 for NO and n=5 for H2O2) These
animals were initially infused with 30% glucose to induce hyperglycemia
then infused continuously with 30% glucose to maintain hyperglycemic
conditions of ≥200 mg/dL throughout the experiment. These groups were
used to demonstrate real-time NO and H2O2 under hyperglycemic conditions
with the addition of a higher dose of the NOX1 inhibitor.

Outline of Experiment
1. Calibrations
2. Animal preparationsa. femoral veins: NO and H2O2 sensors
b. Jugular vein: IV infusion with one of experimental group variations
c. Carotid artery: measure MABP
3. Run experiment-180 minutes
a. Record: blood glucose, NO and H2O2 levels, MABP

Statistical Analysis
All data from text and figures were analyzed by ANOVA using post hoc
analysis with the Student- Newman- Keuls post hoc test for pairwise comparison of
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groups, p<0.05 were considered to be statistically significant. They are represented
as mean ± the standard error of the mean (SEM).

21
Results

Acute Hyperglycemia levels maintained among groups
Blood glucose levels among saline control, 30% D-glucose, 30% D-glucose
with 1 M ML171, and 30% D-glucose with 5 M ML171 were illustrated in figure 6.
The saline control remained in normal blood glucose range (<126mg/dL) for the
entire experiment. All three groups treated with 30% D-glucose maintained a blood
glucose level over 200 mg/dL for the 180-minute experiment once fully induced.
The treatment drug, ML171, showed no altering effects on blood glucose levels, for
both the 1 M ML171, and 5 M ML171.

Figure 7. Blood glucose changes throughout 180-minute experiment with 30%
D-glucose. Groups infused with 30% D-glucose maintained blood glucose
levels of ≥200 mg/dL compared to saline (<126mg/dL).

22

Mean Arterial Blood Pressures Remained Normal throughout Experiment
Mean arterial blood pressure (MABP) among saline control, 30% D-glucose,
30% D-glucose with 1 M ML171, and 30% D-glucose with 5 M ML171 were
shown in figure 7. MABP remained in normal range (90-130mmHg) throughout the
experiment. Acute hyperglycemia as well as hyperglycemia combined with ML171
had no effect on MABP, which were similar to that of the saline group.

Figure 8. Mean Arterial Blood Pressure among groups taken every 20 minutes
for 180-minute experiment. MABP among all groups remained remained in
normal range 90-130mmHg for 3 hours.

23
Acute Hyperglycemia Decreased Blood NO compared to Saline Control
Blood NO levels among saline control and 30% D-glucose were demonstrated
in figure 8. The 30% D-glucose group had significant decrease in blood NO levels
after 60-minute infusion compared to the saline control. This marked decrease was
by a mean value of 37.00±5.12 nM relative to saline (P<0.05, n=8). The significant
reduction in blood NO levels continued and was 101.41±10.91 nM relative to the
saline group at the end of the 180-minute infusion (P<0.01, n=8).

Figure 9. The comparison of blood NO levels relative to saline with 30% Dglucose (*p<0.05, **p<0.01 vs saline). Hyperglycemic group had significantly
reduced blood NO levels relative to saline.
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Ml171 attenuated decreased blood NO due to acute hyperglycemia in a dosedependent matter
Blood NO levels among 30% D-glucose, 30% D-glucose with 1 M ML171,
and 30% D-glucose with 5 M ML171 relative to saline are shown in figure 9. The
30% D-glucose group, as previously stated, had a significant decrease in NO from 60
minutes and throughout the rest of the experiment. The blood NO levels were
finally decreased by 101.41±10.91 nM relative to saline (P<0.01, n=8) . By contrast,
the 1 M ML171 attenuated the decrease in blood NO levels with significant
improvement at 100 minutes until the end of experiment. The blood NO levels were
only reduced by 32.93±12.67 nM relative to saline at 180 minutes (P<0.01, n=5). The 5
M ML171 attenuated the decreased blood NO levels even further with significance
seen at 80 minutes into the experiment and continued until completion at 180
minutes with only a slight decrease of 15.46±8.13 nM relative to the saline group
(P<0.01, n=5).
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Figure 10. The comparison of blood NO levels relative to saline among 30% Dglucose, 30% D-glucose with 1μM ML171, and 30% D-glucose with 5μM
ML171(*p<0.05, **p<0.01 vs Glucose). ML171 increases blood NO levels under
hyperglycemia for both 1μM and 5μM ML171 compared to hyperglycemic
group.

Acute Hyperglycemia Increased Blood H2O2 compared to Saline Control
Blood H2O2 levels among saline control and 30% D-glucose are shown figure
10. The 30% D-glucose group had significant increase in blood H2O2 levels after 80
minutes with an elevation of 1.37±0.21 M compared to saline group (P<0.05, n=9).
The increase in blood H2O2 resulted in a final increase at 180- minutes of 3.06±0.42
M compared to saline (P<0.01, n=9).
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Figure 11. The comparison of blood H2O2 levels relative to saline with 30% Dglucose (*p<0.05, **p<0.01 vs saline). Hyperglycemic group had significantly
elevated blood H2O2 levels relative to saline.

Ml171 attenuated increased blood H2O2 due to Acute Hyperglycemia in dose
dependent matter
Blood H2O2 levels among 30% D-glucose, 30% D-glucose with 1 M ML171,
and 30% D-glucose with 5 M ML171 were demonstrated in figure 11. The 30% Dglucose group, as previously stated, had a significant increase in H2O2 starting at 80
minute infusion and continuing until 180 minutes, with a final elevation of 3.06±0.42
M relative to saline (P<0.01, n=9). The 1 M ML171 attenuated the increase in blood
H2O2 levels with significance at 80 minutes as well as at 140 and 180 minutes
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concluding with lower H2O2 levels of 1.20±0.61 M relative to saline (P<0.05, n=8).
The 5 M ML171 attenuated the increased blood H2O2 levels even further with
significance seen starting at just 40 minutes into the experiment and continued until
completion at 180 minutes with blood H2O2 levels resulting 1.79±1.02 M (P<0.01,
n=5) lower than the saline control.

Figure 12. The comparison of blood H2O2 levels relative to saline among 30%
D-glucose, 30% D-glucose with 1μM ML171, and 30% D-glucose with 5μM
ML171(*p<0.05, **p<0.01 vs Glucose). ML171 reduced blood H2O2 levels
under hyperglycemia for both 1μM and 5μM ML171 compared to
hyperglycemic group.
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Discussion
These results indicated that during hyperglycemia the blood NO levels were
significantly reduced over the 3-hour experiment when compared to saline control.
The results also demonstrated that blood H2O2 levels were significantly elevated
over the 3-hour experiment when compared to saline control.
With the addition of ML171, a selective inhibitor of NOX1, the reduced levels
of NO seen in hyperglycemic conditions were attenuated during the 3-hour
experiment. ML171 also attenuated the elevation in blood H2O2 due to
hyperglycemia. The higher dose of ML171 (e.g. 5M) provided more beneficial
effects in restoring blood NO levels and reducing blood H2O2 levels compared to the
lower dose of ML171 (e.g. 1 M).
Acute hyperglycemia has been shown to reduce vascular endothelial
dependent vasodilation. In 1998, Akbaris et al had determined that endotheliumdependent vasodilation is impaired during acute hyperglycemia in both the microand macrocirculation in 20 healthy subjects27. The macrocirculation diameter was
monitored through the brachial artery by using high-resolution ultra sound before
(fasting) and after ingesting 75 g of glucose. The microcirculation diameter was
measured by changes in the erythrocyte flux after acetylcholine iontophoresis.
Their results showed that dilation was greater during fasting compared to
hyperglycemia, suggesting that this impairs dilation. Moreover, animal experiments
also suggest that acute hyperglycemia can induce vascular endothelial dysfunction.
Gross et al, in 2010 came to such conclusions analyzing shear stress to the left
anterior descending coronary arteries(LAD) in dogs. The animals were fasted,
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anesthetized, and infused with different doses of glucose, depending on their group.
The blood flow, diameter and velocity were measured with response to
acetylcholine to measure endothelial function and ROS generation was determined
by fluorescence of myocardial biopsies. This study determined that hyperglycemia
affects endothelial dysfunction in a dose related manner, as well as ROS production,
and decreased shear stress28. The induction of vascular endothelial dysfunction
may also depend on the time length of acute hyperglycemia and blood vessel. This
was seen with McNauty et al in 2011 while measuring the coronary blood flow
velocity and diameter in 12 cardiac transplant patients before and after 60-minute
glucose infusion. They found that although there were higher levels of oxidative
stress, there was no difference in dilated segments or increase blood flow29. They
suggested that the endothelial dysfunction operates over a longer period of time29.
This study directly monitors blood NO levels which may serve as a biomarker
for vascular endothelial dysfunction in real time under acute hyperglycemia. The
current experimental study induced acute hyperglycemia with blood glucose levels
of approximately 200- 300 mg/dL for 3 hours. Results determined that blood NO
levels were significantly reduced in the hyperglycemia group compared to saline
(101.41±10.91 nM; n=8). When considering absolute values from previous studies
such as Giustarini et al. in 2004, which found that by measuring nitrites in the
plasma of 20 healthy patients it depicted relative levels of NO in the blood34. This is
assumed because nitrites are found to be the most concentrated form of storage NO
carrier34. They determined that the average amounts of nitrite in healthy
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individuals were measured to be 221±72 nM34. Relating back to the current study,
NO bioavailability reduction due to hyperglycemia could be very significant.
Many studies indicate that acute hyperglycemia can quickly induce blood
oxidative stress and certain molecules can reverse some effects to an extent. Gross
et al had also found that the effects of superoxide dismutase mimetic 4-hydroxy2,2,6,6,-tetramethylpiperidine-1-oxyl, otherwise known as tempol, normalized the
oscillatory shear stress that was decreased due to hyperglycemia28. Title et al, in
2007 found that Vitamins C and E attenuated the decrease in flow-mediated dilation
caused by hyperglycemia30. Oxidative stress in some studies is analyzed by lipid
peroxidation(LPO). LPO occurs when the free radical attack polyunsaturated FA
and further interacts with heavy metals resulting in alkoxyl or peroxl radical that
can continue a chain reaction21. Iron salts can also react with the LPO, resulting in
membrane structure changes21. LPO may cause further damage to patients with
hyperglycemia and diabetes through oxidation of enzymes, stimulation of
proinflammatory cytokines, degenerative changes, and DNA damage25. Lipid
peroxidation(LPO) is typically measured using Malondialdehyde (MDA) because it is
an end product of LPO and is a tag for oxidative stress. Bastos et al, when studying
the impact of systemic and local LPO level on periodontal inflammation and disease
had found that uncontrolled diabetic patients had 2.5 times higher MDA plasma
levels than non-diabetic, and 1.5 times higher for well controlled diabetic patients25.
LPO was significantly higher in diabetes patients, with a strong correlation
(p<0.0001). They also discovered that there was positive association between local
inflammatory cytokines in the gingival crevicular fluid with diabetic patients. This

31
also supports previous findings about decreased wound healing due to diabetes and
hyperglycemia25. The current study measured oxidative stress through a real-time
micro sensor for H2O2. Real-time H2O2 was measured instead of the SO produced
since SO is quickly converted to H2O2 by superoxide dismutase and is not as stable
as H2O2. The results determined that blood H2O2 levels were significantly elevated
in the hyperglycemia group compared to saline. Although the absolute values of
H2O2 in the blood have been controversial, a recent study by Forman et al. has
complied research and analyzed possible true values for H2O235. They postulate that
the normal range of H2O2 in the blood is between 1-5 µM35. When considering this
with the current study with hyperglycemia increasing blood H2O2 by 3.0 ± 0.5 µM,
the amount of elevation could be significant and detrimental to physiological
conditions.
The application of antioxidants for counteracting the oxidative stress which
participates in cardiovascular diseases is questionable due to failure of clinical trials.
Vitamin E has been the main vitamin of focus for antioxidant capabilities, but
despite promising cohort studies, randomized clinical intervention trials have failed
to show any benefit for preventing atherosclerosis or cardiovascular events33.
There also has been reason to question targeting ROS with antioxidants, because
they may only be specific in reducing the concentration of some ROS, but not the
others33. Therefore, it may be more advantageous to determine the major and initial
source for oxidative stress under hyperglycemia.
NADPH oxidases are responsible for the natural production of SO/H2O2 in the
body. Under physiological conditions this is used to assist the body with innate
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immunity, redox-dependent signaling, and production of hormones33. In
pathological conditions, activation of NADPH oxidases may serve as a key
component in mediating hyperglycemia caused oxidative stress and vascular
endothelial dysfunction. Taye et al found that by inhibiting NADPH oxidase with
apocynin, a specific NAPDH oxidase inhibitor, the elevated levels of their subunit,
p47phox were lower as well as the oxidative stress due to hyperglycemia31. Activated
NADPH oxidase will produce a large amount of SO/H2O2. Moreover, it can cross-talk
and recruit other possible sources of oxidative stress, such as xanthine oxidase,
eNOS uncoupling, and mitochondria, such upregulation of one will activate
another22. Ago, et al has suggested that xanthine oxidoreductase exists in 2 forms in
order to assist in protein catabolism, xanthine dehydrogenase and xanthine
oxidase26. They state, that in oxidative stress, the oxidoreductase exists primarily in
the xanthine oxidase form, producing SO26. Current studies have also identified a
possible “cross-talk” with mitochondria of NADPH oxidases in the vasculature22.
The elevation of NADPH oxidase specific SO and H2O2 causes mitochondrial
dysfunction, leading to the upregulation of SO produced by the mitochondria22. This
production of SO from the mitochondria in turn further activates the NADPH
oxidases. Furthermore, overproduction of ROS from mitochondria can further cause
eNOS uncoupling. The eNOS enzyme is then uncoupled, and instead of forming NO
to protect homeostasis and regulation, eNOS quenches SO and peroxinitrite
(another free radical) is formed. Thus, the futile cycle resulting in endothelial
dysfunction is created. The damage associated with elevated ROS is in part due the
eNOS uncoupling by the SO. The free radical SO quenches NO and forms
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peroxinitite. This is an even more toxic free radical, due to its ability to uncouple
eNOS. This is accomplished by oxidizing the complex as well as its cofactor BH4 18.
NADPH oxidases are expressed throughout the body. NOX1, 2 and 4 are
expressed specifically in the vasculature, with 1 and 2 present in endothelial cells.
NOX1 is also highly expressed in VSMCs26. Bertolet et al has shown that NOX2
inhibition with gp91ds-tat has only shown partial attenuation of H2O2 under
hyperglycemia7. The role of NOX1 in acute hyperglycemia is unclear. Weaver et al,
research had found that NOX1 inhibition can preserve the function of pancreatic
beta cells through the use of ML17111. We found that ML171 can attenuate the
oxidative stressed caused by the upregulated NOX1 during hyperglycemia.
NOX1 inhibition can reduce PKC activation, which is the upstream signaling
of NADPH oxidase activation. In diabetic kidney, NOX1 has been suggested to be
linked to activation of PKC activation8. This is the first proposed feed forward
mechanism of NOX1 with PKC. It was also suggested that NOX1 but not NOX2
mRNA expression was elevated in early hyperglycemia8. NOX1 deficient mice had
reduced oxidative stress and reduced activation of PKC. NOX1 in hyperglycemia
induced oxidative stress and vascular endothelial dysfunction was focus of our
hypothesis.
It was suggested by Youn, et al that NOX1 mediates BMP4-induced eNOS
uncoupling, shown by a diminished BMP4-induced eNOS uncoupling with NOX1
siRNA-transfected cells17. This was demonstrated by eNOS uncoupling present
within endothelial cells when exposed to BMP4 or bone morphological protein 417.
NO is responsible for vasodilation, inhibiting platelet, and white blood cell
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activation. These actions are necessary for maintaining vascular homeostasis. The
product shift of uncoupled eNOS from NO to SO not only diminishes NO
bioavailability that maintains homeostasis, but also increases SO products, which
results in more oxidative stress. The possible mechanism of what may occur in the
instance of blocking NOX1 with its involvement with other enzymes is outlined in
figure 13. The current study found that ML171, a selective NOX1 inhibitor,
significantly reduced acute hyperglycemia-induced H2O2 increase and NO decrease.
The higher dose provided better effects than lower dose.

Figure 13. Possible mechanism of NOX1 activity at the endothelial level. NOX1
may influence other enzymes and their production of SO.
To further understand the role of NOX1 in hyperglycemia-induced vascular
dysfunction and oxidative stress, future studies will be designed to measure blood
nitrite and other oxidative stress indicators such as Malondialdehyde (MDA). The
impact of body temperature on blood NO and H2O2 levels also were measured, NO
levels slightly decreased in the saline control group and there was a slight increase
in H2O2. Future studies could employ westernblot and immunohistochemistry to
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understand the mechanism as well as interaction of NOX1 with mitochondrial ROS,
uncoupled eNOS, and PKC under the present experimental conditions.
Future studies include clarifying the effects of body temperature, to rule out
any variables due to heat loss during experiment. A heating pad will be placed
under the animals for the duration of the study. The long term effects of ML171 has
also not yet been explored, and this could be an additional aspect of future studies.
The results of this study must be considered in light of certain limitations; for
the absolute values could not be measured. The lab has not yet confirmed the blood
plasma for H2O2 and NO, but a method to do so will be incorporated into future
studies. The free radical microsensors used in this study are also sensitive to
movement and other variables, which may influence real-time readings. Future
studies may incorporate other ways to measure NO and H2O2 in real-time by use of
fluorescence kits if a protocol is developed successfully for this experimental design.

Summary
Acute hyperglycemia is harmful, and the futile cycle created by NOX1 and
uncoupling of eNOS is responsible for vascular endothelial damage. Focus on
reduction of oxidative stress by inhibiting NOX1 may prevent the vicious cycle of
causing oxidative stress and NO reduction in the blood due to hyperglycemia.
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